Association of the novel cardiovascular risk factors paraoxonase 1 and cystatin C in type 2 diabetes

被引:24
|
作者
Connelly, Philip W. [1 ,2 ,3 ]
Zinman, Bernard [4 ]
Maguire, Graham F. [1 ]
Mamakeesick, Mary [6 ]
Harris, Stewart B. [7 ]
Hegele, Robert A. [8 ]
Retnakaran, Ravi [4 ]
Hanley, Anthony J. G. [4 ,5 ]
机构
[1] Univ Toronto, St Michaels Hosp, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada
[2] Univ Toronto, Mt Sinai Hosp, Leadership Sinai Ctr Diabet, Dept Med, Toronto, ON M5B 1W8, Canada
[3] Univ Toronto, Mt Sinai Hosp, Leadership Sinai Ctr Diabet, Dept Lab Med & Pathobiol, Toronto, ON M5B 1W8, Canada
[4] Univ Toronto, Dept Med, Toronto, ON M5B 1W8, Canada
[5] Univ Toronto, Dept Nutr Sci, Toronto, ON M5B 1W8, Canada
[6] Sandy Lake Hlth & Diabet Project, Sandy Lake First Nation, ON, Canada
[7] Univ Western Ontario, Ctr Studies Family Med, London, ON, Canada
[8] Univ Western Ontario, Robarts Res Inst, London, ON, Canada
基金
加拿大健康研究院;
关键词
estimated glomerular filtration rate; renal; high density lipoprotein; genotype; polymorphism; aboriginal; CHRONIC KIDNEY-DISEASE; CREATININE-BASED METHODS; OXIDATIVE STRESS; PLASMA-LIPOPROTEINS; RENAL DYSFUNCTION; SERUM CREATININE; GENE-CLUSTER; G148; VARIANT; COMPLICATIONS; PON1;
D O I
10.1194/jlr.P800070-JLR200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Paraoxonase 1 (PON1) has been reported to be associated with proteinuria in subjects with type 2 diabetes mellitus (T2DM). Plasma cystatin C is more accurate than creatinine for identifying stage 3 kidney disease in T2DM. We tested the hypothesis that PON1 and cystatin C would be associated in T2DM subjects from an Aboriginal Canadian community, who are at high risk for the development of nephropathy. PON1 A(-162) G and PON2 Ala148Gly genotypes, cystatin C, HbA1c, high density lipoprotein cholesterol (HDLC), waist circumference (waist), and duration of diabetes were included in the regression analysis with log(e) (In) of PON1 mass as the dependent variable. A regression model including PON2 Ala148Gly genotype, HDLC, and ln cystatin C explained 25.8% of the variance in PON1 mass. Conversely, waist, age, ln HbA1c, ln duration of diabetes, and ln PON1 mass, but not PON2 genotype, explained 38% of the variance in cystatin C. Subjects with cystatin C estimated glomerular filtration rate (eGFR) <60ml/min per 1.73 m(2) (stage 3 kidney disease) had significantly lower PON1 mass compared with subjects with cystatin C-eGFR >60 ml/min per 1.73 m(2). The lower mass of PON1, an anti-inflammatory HDL-associated enzyme, in T2DM with cystatin C-eGFR <60 ml/min per 1.73 m(2) may contribute to their increased risk for cardiovascular disease.-Connelly, P. W., B. Zinman, G. F. Maguire, M. Mamakeesick, S. B. Harris, R. A. Hegele, R. Retnakaran, and A. J. G. Hanley. Association of the novel cardiovascular risk factors paraoxonase 1 and cystatin C in type 2 diabetes. J. Lipid Res. 2009. 50: 1216-1222.
引用
收藏
页码:1216 / 1222
页数:7
相关论文
共 50 条
  • [41] The association between cystatin C and incident type 2 diabetes is related to central adiposity
    Reutens, Anne T.
    Bonnet, Fabrice
    Lantieri, Olivier
    Roussel, Ronan
    Balkau, Beverley
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 (07) : 1820 - 1829
  • [42] Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with Type 2 diabetes mellitus
    Kadoglou, N. P. E.
    Iliadis, F.
    Angelopoulou, N.
    Perrea, D.
    Liapis, C. D.
    Alevizos, M.
    DIABETIC MEDICINE, 2008, 25 (03) : 333 - 340
  • [43] The Association of Epicardial Adipose Tissue with Serum Level of Cystatin C in Type 2 Diabetes
    Murai, Tomomi
    Takebe, Noriko
    Ishigaki, Yasushi
    DIABETES, 2017, 66 : A687 - A687
  • [44] Association of epicardial adipose tissue with serum level of cystatin C in type 2 diabetes
    Murai, Tomomi
    Takebe, Noriko
    Nagasawa, Kan
    Todate, Yusuke
    Nakagawa, Riyuki
    Nakano, Rieko
    Hangai, Mari
    Hasegawa, Yutaka
    Takahashi, Yoshihiko
    Yoshioka, Kunihiro
    Ishigaki, Yasushi
    PLOS ONE, 2017, 12 (09):
  • [45] Prevalence of the metabolic syndrome and associated novel cardiovascular risk factors in patients with Type 2 diabetes
    Bianchi, C
    Penno, G
    Giovannitti, MG
    Pucci, L
    Pellegrini, G
    Caricato, E
    Bertolotto, A
    Corfini, M
    Del Prato, S
    Miccoli, R
    DIABETOLOGIA, 2004, 47 : A124 - A125
  • [46] Metabolic syndrome in Type 1 and Type 2 diabetes mellitus and its association with high cardiovascular risk
    Reddy, H.
    Gopinath, A.
    Morrissey, J.
    Patel, V.
    DIABETIC MEDICINE, 2007, 24 : 55 - 56
  • [49] Association of a Cystatin C Gene Variant With Cystatin C Levels, CKD, and Risk of Incident Cardiovascular Disease and Mortality
    O'Seaghdha, Conall M.
    Tin, Adrienne
    Yang, Qiong
    Katz, Ronit
    Liu, YongMei
    Harris, Tamara
    Astor, Brad
    Coresh, Josef
    Fox, Caroline S.
    Kao, W. H. Linda
    Shlipak, Michael G.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2014, 63 (01) : 16 - 22
  • [50] Reducing the cardiovascular risk at patients with type 2 diabetes by controlling the risk factors
    Tudor, C.
    Jeberean, R. A.
    Buzas, R.
    Popescu, A.
    Ionita, M.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 346 - 346